Skip to main content

Bolstered pathway to profitability

The $30m placement conducted last week significantly strengthens the PolyNovo balance sheet. This provides the growth platform facilitating the expansion of the US and global sales team with key markets in Asia (India, Hong Kong, China, Japan) & Canada being targeted. An important driver in US commercialisation has been through additional commercial hires and the capital raising allows acceleration with this process. The company intends to hire ~ 30 new staff during FY23. Product launch within Hong Kong and India has already taken place during 1H23 whilst entry into Japan/China is planned through a distributor model. These new operating segments increase the addressable market especially in regions with a significant healthcare burden of burns and complex/trauma wounds. Recent BTM registration within Canada is also an important achievement as this simplifies the process to use BTM which was previously only accessible via the Canadian Special Access scheme on a case-by-case basis.

Overview of funds allocation

The company intends to use the $33m ($30m placement, $3m director placement subject to shareholder approval at EGM in January 2023) in geographical expansion through additional hiring ($6m) and manufacturing facility extension ($25m) to facilitate annual revenue capacity of ~ $500m and accelerate R&D projects (breast, hernia devices, therapeutics). Expanding indications involve BTM and MTX devices with the launch of SynPath in the diabetic foot ulcer market targeted in late CY23.

Investment view: Maintain Buy, Increase PT to $2.30

Our price target is now generated purely from our DCF methodology as this best captures the longer-term earning potential for PNV. The strengthened balance sheet reduces financial risk and accordingly we decrease the WACC from 10.3% to 10.0%. Combining these strategic developments, we expect PNV to be profitable from FY24 in line with company expectations and this growth strategy to translate to improved earnings in the medium- to long-term (FY26 onwards).

To read the full report click the button below.

View Detailed Report
Authored by Dr Anubhav Saxena – Analyst – at Bell Potter Securities, 1 December 2022
Important Disclaimer—This may affect your legal rights: Because this document has been prepared without consideration of any specific client’s financial situation, particular needs and investment objectives, a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the proper authority of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be consulted before any investment decision is made. While this document is based on the information from sources which are considered reliable, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. This is general investment advice only and does not constitute advice to any person.
Disclosure of Interest: Bell Potter Securities Limited receives commission from dealing in securities and its authorised representatives, or introducers of business, may directly share in this commission. Bell Potter Securities and its associates may hold shares in the companies recommended.